Associated Factors to Human Papillomavirus Vaccine Adhesion in Adult Women: a Cross-sectional Study

Overview

Journal Porto Biomed J

Publisher Wolters Kluwer

Specialty Biomedical Engineering

Date 2023 May 22

PMID 37213246

Authors

Rita Sarabando

Ana Vilela-Gomes

Isabel Reis

Amalia Pacheco

Cristina Nogueira-Silva

Affiliations

Soon will be listed here.

Abstract

Background: The goal of human papillomavirus (HPV) vaccination is the decline of HPV related premalignant lesions, leading to prevention of cervical cancer. Vaccination against HPV is recommended until the age of 45 to prevent viral reinfections and reactivations. The aim of this study was to evaluate adhesion to HPV vaccination and their associated factors in adult women.

Methods: Cross-sectional study in two tertiary hospitals, with a questionnaire distributed to women born between 1974 and 1992, from September till November 2019. Data collected included sociodemographic information, clinical information, knowledge about HPV, and the HPV vaccine and data regarding vaccine recommendation. Factors associated with vaccination were searched by bivariate and multivariate statistical analysis.

Results: In 469 questionnaires, 25.4% (n = 119) women were vaccinated. The main reason for not vaccinating was the non-recommendation (n = 276; 70.2%). In bivariate analyses, vaccinated women were younger, predominantly not married, had higher educational level, and higher careers ( ≤ .001); an abnormal cytology, HPV infection or previous excision of the transformation zone were associated with a 3 to 4-fold increase in the odds of vaccination. Age, high-risk HPV infection, and knowing someone vaccinated remained factors independently associated with HPV vaccination in the multivariate analyses (< .05). The recommendation of "vaccinate immediately" was independently associated with effectively doing it (< .001).

Conclusions: HPV vaccination is associated with vaccine recommendation, especially if it is recommended to do immediately. These results reinforce the need of health professionals to be aware of the impact that their recommendation has on adhesion to HPV vaccination.

References

Castellsague X, Munoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K . End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011; 105(1):28-37. PMC: 3137403. DOI: 10.1038/bjc.2011.185. View

Brianti P, De Flammineis E, Mercuri S . Review of HPV-related diseases and cancers. New Microbiol. 2017; 40(2):80-85. View

Kum-Nji P, Meloy L, Keyser-Marcus L . Tobacco smoke exposure as a risk factor for human papillomavirus infections in women 18-26 years old in the United States. PLoS One. 2019; 14(10):e0223532. PMC: 6821098. DOI: 10.1371/journal.pone.0223532. View

Berenson A, Brown V, Fuchs E, Hirth J, Chang M . Relationship between maternal experiences and adolescent HPV vaccination. Hum Vaccin Immunother. 2017; 13(9):2150-2154. PMC: 5612520. DOI: 10.1080/21645515.2017.1332551. View

Garland S, Kjaer S, Munoz N, Block S, Brown D, DiNubile M . Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016; 63(4):519-27. PMC: 4967609. DOI: 10.1093/cid/ciw354. View

Gilkey M, Calo W, Moss J, Shah P, Marciniak M, Brewer N . Provider communication and HPV vaccination: The impact of recommendation quality. Vaccine. 2016; 34(9):1187-92. PMC: 4944755. DOI: 10.1016/j.vaccine.2016.01.023. View

Joura E, Giuliano A, Iversen O, Bouchard C, Mao C, Mehlsen J . A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8):711-23. DOI: 10.1056/NEJMoa1405044. View

Garland S, Brotherton J, Moscicki A, Kaufmann A, Stanley M, Bhatla N . HPV vaccination of immunocompromised hosts. Papillomavirus Res. 2017; 4:35-38. PMC: 5883202. DOI: 10.1016/j.pvr.2017.06.002. View

Lenselink C, Schmeink C, Melchers W, Massuger L, Hendriks J, van Hamont D . Young adults and acceptance of the human papillomavirus vaccine. Public Health. 2008; 122(12):1295-301. DOI: 10.1016/j.puhe.2008.02.010. View

10.

Sousa H, Tavares A, Campos C, Marinho-Dias J, Brito M, Medeiros R . High-Risk human papillomavirus genotype distribution in the Northern region of Portugal: Data from regional cervical cancer screening program. Papillomavirus Res. 2019; 8:100179. PMC: 6702237. DOI: 10.1016/j.pvr.2019.100179. View

11.

de Oliveira C, Fregnani J, Villa L . HPV Vaccine: Updates and Highlights. Acta Cytol. 2019; 63(2):159-168. DOI: 10.1159/000497617. View

12.

Wheeler C, Skinner S, Del Rosario-Raymundo M, Garland S, Chatterjee A, Lazcano-Ponce E . Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet Infect Dis. 2016; 16(10):1154-1168. DOI: 10.1016/S1473-3099(16)30120-7. View

13.

Pista A, de Oliveira C, Cunha M, Paixao M, Real O . Prevalence of human papillomavirus infection in women in Portugal: the CLEOPATRE Portugal study. Int J Gynecol Cancer. 2011; 21(6):1150-8. DOI: 10.1097/IGC.0b013e31821dd3b2. View

14.

Castle P, Maza M . Prophylactic HPV vaccination: past, present, and future. Epidemiol Infect. 2015; 144(3):449-68. DOI: 10.1017/S0950268815002198. View

15.

Kornides M, Fontenot H, McRee A, Panozzo C, Gilkey M . Associations between parents' satisfaction with provider communication and HPV vaccination behaviors. Vaccine. 2018; 36(19):2637-2642. PMC: 5915964. DOI: 10.1016/j.vaccine.2018.03.060. View

16.

Rosenthal S, Weiss T, Zimet G, Ma L, Good M, Vichnin M . Predictors of HPV vaccine uptake among women aged 19-26: importance of a physician's recommendation. Vaccine. 2010; 29(5):890-5. DOI: 10.1016/j.vaccine.2009.12.063. View

17.

Leto M, Santos Junior G, Porro A, Tomimori J . Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations. An Bras Dermatol. 2011; 86(2):306-17. DOI: 10.1590/s0365-05962011000200014. View

18.

Darden P, Jacobson R . Impact of a physician recommendation. Hum Vaccin Immunother. 2014; 10(9):2632-5. PMC: 4975061. DOI: 10.4161/hv.29020. View

19.

Rwamwejo J, Ramos S, Morgan K, Richter K, Kim C, Peris M . Persuasive messaging for human papillomavirus vaccination by adolescent providers in a five-country multi-site study. Int J Gynecol Cancer. 2019; 29(2):250-256. DOI: 10.1136/ijgc-2018-000004. View

20.

Ghelardi A, Parazzini F, Martella F, Pieralli A, Bay P, Tonetti A . SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol. 2018; 151(2):229-234. DOI: 10.1016/j.ygyno.2018.08.033. View